1. C60-fullerenes for delivery of docetaxel to breast cancer cells: A promising approach for enhanced efficacy and better pharmacokinetic profile.
- Author
-
Raza, Kaisar, Thotakura, Nagarani, Kumar, Pramod, Joshi, Mayank, Bhushan, Shashi, Bhatia, Amit, Kumar, Vipin, Malik, Ruchi, Sharma, Gajanand, Guru, Santosh Kumar, and Katare, O.P.
- Subjects
- *
BREAST cancer treatment , *BUCKMINSTERFULLERENE , *DOCETAXEL , *DRUG efficacy , *PHARMACOKINETICS , *DRUG delivery systems - Abstract
Docetaxel has always attracted the researchers owing to its promises and challenges. Despite marked efficacy, concerns like poor aqueous solubility, lower bioavailability, poor tissue penetration and dose related side-effects offer further scope of research on docetaxel. The present study aims to explore the potential of C 60 -fullerenes in the delivery of docetaxel to cancerous cells. C 60 -fullerenes were carboxylated, acylated and conjugated with the drug. The chemical processes were monitored by UV, FT-IR and NMR spectroscopy. The conjugate was further characterized for drug loading, micromeritics, drug release, morphology and evaluated for in-vitro cytotoxicity, haemolysis and in-vivo pharmacokinetic profile. The developed nanoconstruct was able to enhance the bioavailability of docetaxel by 4.2 times and decrease the drug clearance by 50%. The developed system was able to control the drug release and was found to be compatible with erythrocytes. The cytotoxic potential on studied MCF-7 and MDA-MB231 cell lines was also enhanced by many folds, indicating marked promise in efficacy enhancement and dose reduction. The present findings are encouraging and offer a technique to enhance the delivery and efficacy potential of anticancer agents, especially belonging to BCS class IV. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF